LEGN analyst estimates
Legend Biotech (LEGN) analyst ratings, the average price target and its range, and every firm's latest call.
LEGN analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 8, 2026 | RBC Capital | Legend Biotech price target lowered to $56 from $58 at RBC Capital | $56.00 |
| Sep 28, 2026 | UBS | H.C. Wainwright Reiterates Buy Rating on Legend Biotech Corp. (LEGN) | $65.00 |
| Sep 4, 2026 | Morgan Stanley | H.C. Wainwright Reiterates Buy Rating on Legend Biotech Corp. (LEGN) | $65.00 |
| Aug 12, 2026 | Barclays | Legend Biotech price target lowered to $78 from $80 at Barclays | $78.00 |
| Aug 12, 2026 | Oppenheimer | Oppenheimer downgrades Legend Biotech to Perform on CEO/competition overhangs | $40.00 |
| Jul 27, 2026 | RBC Capital | Legend Biotech price target lowered to $59 from $63 at RBC Capital | $59.00 |
| Jul 27, 2026 | Raymond James | Legend Biotech Corp. (LEGN) PT Lowered to $58 at Raymond James | $58.00 |
| Jul 24, 2026 | UBS | Legend Biotech downgraded to Neutral from Buy at UBS | $28.00 |
| Jul 7, 2026 | RBC Capital | Legend Biotech price target lowered to $63 from $64 at RBC Capital | $63.00 |
| Jun 3, 2026 | H.C. Wainwright | Legend Biotech price target raised to $65 from $50 at H.C. Wainwright | $65.00 |
| Jun 3, 2026 | UBS | Legend Biotech Corp. (LEGN) PT Raised to $49 at UBS | $49.00 |
| Jun 1, 2026 | UBS | H.C. Wainwright Reiterates Buy Rating on Legend Biotech Corp. (LEGN) | $50.00 |
| May 13, 2026 | Morgan Stanley | Legend Biotech price target lowered to $48 from $49 at Morgan Stanley | $48.00 |
| May 13, 2026 | RBC Capital | Legend Biotech price target raised to $64 from $62 at RBC Capital | $64.00 |
| Mar 11, 2026 | Morgan Stanley | Legend Biotech price target lowered to $49 from $50 at Morgan Stanley | $49.00 |
- 9 firms rate LEGN: 5 buy, 4 hold, 0 sell.
- The average price target is $61.00 from 7 analysts, from $40.00 to $78.00.
Updated 2026-11-03 11:27 UTC